Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Post by dt_coreon Mar 22, 2011 8:25am
290 Views
Post# 18320530

Q4 Disapointing. But 2011 Very Strong

Q4 Disapointing. But 2011 Very StrongI guess we know why HEM decided to postpone its conference call. Without question Q4 was a disapointment and well below the streets estimates. However, 2011 appears to be very promissing. Essentially the company has now reported 1Q11 revenue at around $21.5mm, which is very positive and in line with most analyst estimates (being able to provide this info is clearly why the company delayed its conf call until today). Management is saying at least 25% increase for all of 2011 is being forecasted (or $70mm+ revenue). Again this is very positive and in line with street expectations for 2011. Also, don't discount the return to profitability comments which will be a key to driving the share price north of $3.00 (we won't get there without profits).

Honestly, not sure what to expect today. The street might get spooked by the headline numbers so potential for some selling early. Conference call is the key now as management needs to give more guidance on margins and how they are managing the currency hedge they've implemented.

Looking ahead we now have true fundamentals to support at least a $2.00 share price based on 1Q11 actual (well, almost actual as still a few days left in the quarter) and strong outlook. $3.00 is still in the cards but will take reporting 2Q11 or another major announcment so I suspect by summer we'll get there (or close) assuming no major disruptions to business fundamentals (I don't anticipate any).
Bullboard Posts